Compare AWP & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWP | KALA |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.7M | 319.6M |
| IPO Year | N/A | 2017 |
| Metric | AWP | KALA |
|---|---|---|
| Price | $11.11 | $0.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 128.0K | ★ 7.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | ★ 41.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.27 | $0.22 |
| 52 Week High | $12.71 | $20.58 |
| Indicator | AWP | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 29.43 |
| Support Level | $3.80 | N/A |
| Resistance Level | $12.71 | $0.72 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.33 | -0.00 |
| Stochastic Oscillator | 0.00 | 1.48 |
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.